fr   en
Fundraisings
Select a company :
Select an investor :
Choose date:
[<<]      «      5   |   6   |   7   |   8   |   9   |   10   |   11   |   12   |   13   |   14   |   15      »      [23]
Date Company Amount Investors Planned use / Other
2009-08-06 Vernalis (UK) $ 3 million (€ 2.09 million) GSK (UK) See details
2009-08-06 Oncodesign (France) € 10 million French innovation agency OSEO (France) See details
2009-08-04 Oramed Pharmaceuticals (Israel) NIS 3.1 million ($828,000) Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor (Israel) See details
2009-07-29 Apogenix (Germany) € 2.6 million Biotechnology Cluster Rhine-Neckar (Germany)
See details
2009-07-08 Exonhit Therapeutics (France) € 1.45 million   See details
2009-07-08 Affectis Pharmaceuticals €550.000 Bavarian Ministry of Economics (Germany) See details
2009-07-06 Novacta Biosystems (UK) £13.1 million Celtic Pharma Holdings (UK) See details
2009-07-02 TopoTarget (Denmark) DKK 132.6 million (€ 17.8 million) existiing shareholders See details
2009-07-02 Affitech (Denmark) DKK 26.8 million (€ 3.6 million) Existing group of shareholders comprising Ferd AS, Arendals Fossekompani ASA, Braganza AS, Teknoinvest VII KS, Verdane Capital IV TWIN AS, Anchor Secondary 3 Holding AS, Sarsia Life Science Fund AS, Glastad Invest AS, Lene AS, Hans Bjarne Dahl, John McDougall, Kerstin Maria Hareide, Marike Stassar and Amino AS. See details
2009-07-01 NovoCIB (France) € 200,000 Business Angels of the Savoie-Angels association
and its investment fund, Allobroges Participations (France)
See details
2009-06-29 Pronota (Belgium) € 4.9 million LSP (The Netherlands - Germany - USA)
GIMV (Belgium)
Biotech Fund Flanders (Belgium)
KBC Private Equity (Belgium)
Johnson & Johnson Development Corporation (USA)
Baekeland Fund (Belgium)
VIB (Belgium)
See details
2009-06-26 Clavis Pharma (Norway) NOK 129 million (€ 14.3 million) + NOK 7.8 million (€ 1 million) existing life science and institutional investors including NeoMed Management and MVM Life Science Partners
new institutional investors
See details
2009-06-23 Regen Therapeutics (UK) £30,000 (€35265) one existing shareholder See details
2009-06-23 Chroma Therapeutics (UK) £15 million GSK (UK)
Abingworth Management (UK)
Essex Woodlands Healthcare Ventures (UK/USA)
Gilde Healthcare (The Netherlands)
Nomura Phase4 Ventures (UK)
The Wellcome Trust (UK)
See details
2009-06-18 Lumavita (Switzerland) CHF6 million (€4 million) HealthCap (Sweden)
Endeavour Vision (Switzerland)
See details
[<<]      «      5   |   6   |   7   |   8   |   9   |   10   |   11   |   12   |   13   |   14   |   15      »      [23]